Papers/PMID:25261882
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.
Schizophrenia research2014The record
9 findings · 1 compound · 9 endpoints · 7 null
What it reported
How to read these marksWhat moved
2 findings
pravastatin — decreases LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Pravastatin use was associated with a significantly greater decrease from baseline to week 6 and baseline to week 12 in LDL cholesterol (Week 6 – Baseline ANCOVA: p<.0001 and Week 12 – Baseline ANCOVA: p=0.0003), total cholesterol (Week 6 – Baseline ANCOVA: p<0001 and Week 12 – Baseline ANCOVA: p=0.001), and small LDL particle numbers (Week 6 – Baseline ANCOVA: p= 0.05 and Week 12 – Baseline ANCOVA: p=0.009).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Pravastatin use was associated with a significantly greater decrease from baseline to week 6 and baseline to week 12 in LDL cholesterol (Week 6 – Baseline ANCOVA: p<.0001 and Week 12 – Baseline ANCOVA: p=0.0003), total cholesterol (Week 6 – Baseline ANCOVA: p<0001 and Week 12 – Baseline ANCOVA: p=0.001), and small LDL particle numbers (Week 6 – Baseline ANCOVA: p= 0.05 and Week 12 – Baseline ANCOVA: p=0.009).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
What did not
7 findings
pravastatin — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — no detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — no detected effect on interleukin-6 concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — no detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use was not significantly associated with change in glucose metabolism measurements such as fasting glucose, fasting insulin, HOMA-IR (homeostasis model of assessment of insulin resistance) and HbA1c (hemoglobin A1c) from baseline to either week 6 or week 12 (table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline at week 6 and week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — no detected effect on tumour necrosis factor alpha concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
pravastatin — no detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use was not significantly associated with change in glucose metabolism measurements such as fasting glucose, fasting insulin, HOMA-IR (homeostasis model of assessment of insulin resistance) and HbA1c (hemoglobin A1c) from baseline to either week 6 or week 12 (table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline at week 6 and week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
Show the remaining 1
pravastatin — no detected effect on HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use was not significantly associated with change in glucose metabolism measurements such as fasting glucose, fasting insulin, HOMA-IR (homeostasis model of assessment of insulin resistance) and HbA1c (hemoglobin A1c) from baseline to either week 6 or week 12 (table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline at week 6 and week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink